Papua New Guinea vs Vanuatu: Hepatitis B surface antigen (HBsAg) prevalence
Papua New Guinea
2.5%
in 2024
Vanuatu
1.8%
in 2024
Papua New Guinea rank
10th
Vanuatu rank
13th
Hepatitis B surface antigen (HBsAg) prevalence over time
- Papua New Guinea
- Vanuatu
How they compare
Papua New Guinea currently reports 2.5% against 1.8% in Vanuatu, a difference of 0.7%.
That makes Papua New Guinea's figure about 1.4 times Vanuatu's.
Across all 10 years both countries report, Papua New Guinea has been ahead every year.
Papua New Guinea ranks 10th and Vanuatu ranks 13th of 194 countries.
Papua New Guinea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Papua New Guinea | Vanuatu | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2.0% | 1.6% | 0.3% | Papua New Guinea |
| 2020s | 2.4% | 1.7% | 0.8% | Papua New Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Papua New Guinea or Vanuatu?
- Papua New Guinea, at 2.5% against 1.8% in Vanuatu as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Papua New Guinea and Vanuatu?
- 0.7%, with Papua New Guinea ahead.
- How many years of comparable data are there for Papua New Guinea and Vanuatu?
- 10 years are reported by both, from 2015 to 2024.
- How do Papua New Guinea and Vanuatu rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Papua New Guinea ranks 10th and Vanuatu ranks 13th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.